CHM — Chimeric Therapeutics Cashflow Statement
0.000.00%
- AU$7.88m
- AU$5.32m
Annual cashflow statement for Chimeric Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | — | — | -0.003 | 3.53 | 12.9 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -0.034 | -8.84 | -13.2 | -16.3 | -7.54 |
Capital Expenditures | — | -5.31 | -0.538 | -0.112 | — |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0 | 0.003 | -0.04 | 0 | — |
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0 | -5.3 | -0.578 | -0.112 | — |
Financing Cash Flow Items | — | -2.72 | -1.31 | -0.099 | -1.21 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.034 | 36.5 | 9.54 | 0.253 | 8.26 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0 | 22.4 | -4.03 | -16 | 0.69 |